Pall Corporation is unveiling its expanded line of upstream and downstream capabilities including new single-use technologies for biopharmaceutical manufacturing at INTERPHEX 2014, booths 3021 and 3341. The show runs from March 18-20 at the Jacob K. Javits Center in New York.
With the recent acquisitions of the LifeSciences business of ATMI, Medistad Holding BV and SoloHill Engineering Inc., Pall strengthened its upstream capabilities and already-established portfolio of single-use technologies. The company can now offer customers multiple solutions for their single-use applications. At INTERPHEX, the company’s extended suite of products is on display for the first time.
Following are new innovations Pall will be introducing at INTERPHEX:
The Allegro STR 200 Single-use Bioreactor System is used for production-scale applications and is currently available in working volumes up to 200L. The single-use stirred tank bioreactor features excellent mixing and mass transfer characteristics for upflow or downflow operations with minimum shear.
The next generation of connector technology comes in the form of the Kleenpak II sterile connector, which offers a robust solution for large-scale, high-volume sterile fluid transfer. Available in 3Ž4 and 1” fittings, this connector enables secure, permanent connections for single-use or hybrid systems over 100L in volume.
Among the innovations from Pall’s acquisitions being introduced is an expanded range of cubical and round single-use tanks for biopharmaceutical and pharma mixing applications. There are 64 tanks designed for use, from bench to commercial scale, featuring standard options including state-of-the-art, ASME-certified insulated jackets and load cells with displays. All of the tanks in the range are made from standard materials, with consistent finishes and fully sealed frames.
The off-the-shelf LevPak system, part of the Integrity product line that uses TK8 film, is the only product on the market that enables mixing, storage, shipping, remixing and dispensing of final biopharmaceutical and vaccine products in a single unit. It replaces traditional shipping methods like glass or plastic bottles, and removes the need for additional process steps once a customer receives product, as it is ready to be mixed in situ.
EP News Bureau – Mumbai
- Advertisement -
